Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro in vivo

International Immunology

Volumn 15, Issue 7, 2003, Pages 789-796

  Zocher, Marcel ^a,c   Baeuerle, Patrick A ^a   Dreier, Torsten ^a   Iglesias, Antonio ^b,c  

^a MICROMET AG   (Germany)

^b MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Autoantibodies; Autoimmunity; Fusion protein; Myelin oligodendrocyte glycoprotein

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN HEAVY CHAIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DIMERIZATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG SPECIFICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYBRIDOMA CELL CULTURE; IMMUNE RESPONSE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; TISSUE INJURY;

EID: 0038012786     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/dxg076     Document Type: Article

References (24)

1. Hohlfeld, R. 1997. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120:865.
2. Genain, C. P., Cannella, B., Hauser, S. L. and Raine, C. S. 1999. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5:170.
3. Storch, M. K., Piddlesden, S., Haltia, M., Iivanainen, M., Morgan, P. and Lassmann, H. 1998. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 43:465.
4. Baranzini, S. E., Jeong, M. C., Butunoi, C., Murray, R. S., Bernard, C. C. and Oksenberg, J. R. 1999. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J. Immunol. 163:5133.
5. Colombo, M., Dono, M., Gazzola, P., Roncella, S., Valetto, A., Chiorazzi, N., Mancardi, G. L. and Ferrarini, M. 2000. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J. Immunol. 164:2782.
6. H genes of B cells from cerebrospinal fluid in multiple sclerosis. J. Clin. Invest. 102:1045.
7. Iglesias, A., Bauer, J., Litzenburger, T., Schubart, A. and Linington, C. 2001. T- and B cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 36:220.
8. Weinshenker, B. G., O'Brien, P. C., Petterson, T. M., Noseworthy, J. H., Lucchinetti, C. F., Dodick, D. W., Pineda, A. A., Stevens, L. N. and Rodriguez, M. 1999. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol. 46:878.
9. Leget, G. A. and Czuczman, M. S. 1998. Use of rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 10:548.
10. Weinshenker, B. G. 1999. Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. J. Clin. Apheresis 14:144.
11. Bernard, C. C., Johns, T. G., Slavin, A., Ichikawa, M., Ewing, C., Liu, J. and Bettadapura, J. 1997. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J. Mol. Med. 75:77.
12. Gardinier, M. V., Amiguet, P., Linington, C. and Matthieu, J. M. 1992. Myelin/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily. J. Neurosci. Res. 33:177.
13. Litzenburger, T., Fassler, R., Bauer, J., Lassmann, H., Linington, C., Wekerle, H. and Iglesias, A. 1998. B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. J. Exp. Med. 188:169.
14. Raum, T., Gruber, R., Riethmuller, G. and Kufer, P. 2001. Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens. Cancer Immunol. Immunother. 50:141.
15. - dendritic cells in the induction of primary immune responses in vivo. J. Leukoc. Biol. 66:242.
16. Kreitman, R. J. 1999. Immunotoxins in cancer therapy. Curr. Opin. Immunol. 11:570.
17. Pai, L. H., Batra, J. K., FitzGerald, D. J., Willingham, M. C. and Pastan, I. 1991. Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin. Proc. Natl Acad. Sci. USA 88:3358.
18. Rammensee, H. G., Julius, M. H., Nemazee, D., Langhorne, J., Lamers, R. and Kohler, G. 1987. Targeting cytotoxic T cells to antigen-specific B lymphocytes. Eur. J. Immunol. 17:433.
19. Baselga, J., Norton, L., Albanell, J., Kim, Y. M. and Mendelsohn, J. 1998. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:2825.
20. Hainsworth, J. D. 2000. Rituximab as first-line systemic therapy for patients with low-grade lymphoma. Semin. Oncol. 27:25.
21. Ober, R. J., Radu, C. G., Ghetie, V. and Ward, E. S. 2001. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol. 13:1551.
22. Wines, B. D., Powell, M. S., Parren, P. W., Barnes, N. and Hogarth, P. M. 2000. The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. J. Immunol. 164:5313.
23. Link, H., Olsson, O., Sun, J., Wang, W. Z., Andersson, G., Ekre, H. P., Brenner, T., Abramsky, O. and Olsson, T. 1991. Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J. Clin. Invest. 87:2191.
24. Nishifuji, K., Amagai, M., Kuwana, M., Iwasaki, T. and Nishikawa, T. 2000. Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J. Invest. Dermatol. 114:88.